| PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention. Results of the PRODIGY trial. | Hot Line III - Acute coronary syndromes | Marco Valgimigli - Adnan Kastrati | Percutaneous Cardiovascular Intervention (PCI) | 30 Aug 2011 |
| The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome | Hot Line III - Acute coronary syndromes | Philippe Gabriel Steg - Steen Dalby Kristensen | Acute Coronary Syndromes (ACS) | 30 Aug 2011 |
| The EXAMINATION Trial: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction | Hot Line III - Acute coronary syndromes | Manel Sabate Tenas - William Wijns | Percutaneous Cardiovascular Intervention (PCI) | 30 Aug 2011 |
| Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents | Hot Line III - Acute coronary syndromes | Lorenz Raber - Jean Fajadet | Percutaneous Cardiovascular Intervention (PCI) | 30 Aug 2011 |
| CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial | Hot Line III - Acute coronary syndromes | Manesh Patel - Kurt Huber | Acute Coronary Syndromes (ACS) | 30 Aug 2011 |
| EVATEL: Remote follow-up of patients implanted with an ICD: the prospective randomized EVATEL study. | Hot Line II - Frontiers in interventional and device treatments | Philippe Mabo - Angelo Auricchio | Arrhythmias | 29 Aug 2011 |
| ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial | Hot Line II - Frontiers in interventional and device treatments | Salem Kacet - Jean-Claude Daubert | Arrhythmias | 29 Aug 2011 |
| EMPHASIS-HF - The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in the study population | Hot Line II - Frontiers in interventional and device treatments | Bertram Pitt - Piotr Ponikowski | Heart Failure (HF) | 29 Aug 2011 |
| RESET: One-year outcome of the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial | Hot Line II - Frontiers in interventional and device treatments | Takeshi Kimura - Stephan Windecker | Percutaneous Cardiovascular Intervention (PCI) | 29 Aug 2011 |
| Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI/CABG registry Cohort-2 | Hot Line II - Frontiers in interventional and device treatments | Hiroki Shiomi - Frans Van de Werf | Percutaneous Cardiovascular Intervention (PCI) | 29 Aug 2011 |
| SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapy | Clinical Trial Update II - Rate and rhythm | Michael R Gold - Cecilia Linde | Heart Failure (HF) | 29 Aug 2011 |
| PACE: Biventricular pacing superior to right ventricular pacing in bradycardia patients with preserved systolic function: two-year results of PACE trial | Clinical Trial Update II - Rate and rhythm | Cheuk-Man Yu - Kenneth Dickstein | Arrhythmias | 29 Aug 2011 |
| IRIS: Why does the implantable cardioverter-defibrillator not improve mortality early after myocardial infarction - Insights from the Immediate Risk Stratification Improves Survival (IRIS) trial | Clinical Trial Update II - Rate and rhythm | Gerhard Steinbeck - Christophe Leclercq | Arrhythmias | 29 Aug 2011 |
| SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFT | Clinical Trial Update II - Rate and rhythm | Inger Ekman - Erland Erdmann | Heart Failure (HF) | 29 Aug 2011 |
| SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-study | Clinical Trial Update II - Rate and rhythm | Jean-Claude Tardif - Burkert Mathias Pieske | Heart Failure (HF) | 29 Aug 2011 |
| STICH: Influence of mitral valve repair on survival in the surgical treatment for Ischemic heart failure trial | Clinical Trial Update II - Rate and rhythm | Marek Deja - Alec Vahanian | Heart Failure (HF) | 29 Aug 2011 |
| The Italian Elderly ACS study: Early aggressive versus initially conservative strategy in elderly patients with non-ST- elevation acute coronary syndrome: the Italian Elderly ACS randomised trial (ClinicalTrials.gov ID: NCT00510185) | Clinical Registry Highlight II - Interventions and devices | Stefano Savonitto | Acute Coronary Syndromes (ACS) | 29 Aug 2011 |
| Is clopidogrel discontinuation following acute coronary syndrome hospitalisation associated with a higher risk of death and myocardial infarction? | Clinical Registry Highlight II - Interventions and devices | Adam Timmis | Acute Coronary Syndromes (ACS) | 29 Aug 2011 |
| DK: Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a nationwide study of 7.4 million individuals | Clinical Registry Highlight II - Interventions and devices | Borge Nordestgaard | Acute Coronary Syndromes (ACS) | 29 Aug 2011 |
| The European CRT survey: 1 year follow-up results | Clinical Registry Highlight II - Interventions and devices | Nigussie Bogale | Arrhythmias | 29 Aug 2011 |
| Mitochondrial localization unveils a novel role for GRK2 in the regulation of oxidative metabolism. | Basic and Translational Science Hot Line | Anna Fusco | Clinical pharmacology | 29 Aug 2011 |
| Antibody-coupling and targeting of microbubbles to activated platelets allows molecular imaging of thrombosis and monitoring of success or failure of thrombolysis using non-invasive ultrasound. | Basic and Translational Science Hot Line | Karlheinz Peter | Non-invasive imaging: Echocardiography, MR/CT, Nuclear | 29 Aug 2011 |
| Modeling of Familial Dilated Cardiomyopathy Caused by Mutation in Lamin A/C Gene Using Patient-Specific Induced Pluripotent Stem Cells | Basic and Translational Science Hot Line | Chung Wah Siu | Clinical pharmacology | 29 Aug 2011 |
| A critical role for STIM1 in cardiac hypertrophy | Basic and Translational Science Hot Line | Jean-Sebastien Hulot | Genetics | 29 Aug 2011 |
| Hemoglobin Directs Macrophage Differentiation and Prevents Foam Cell Formation in Human Atherosclerotic Plaques | Basic and Translational Science Hot Line | Aloke Finn | Clinical pharmacology | 29 Aug 2011 |
| miR-145: A role in the development of pulmonary arterial hypertension | Basic and Translational Science Hot Line | Paola Caruso | Pulmonary Hypertension | 29 Aug 2011 |
| PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 people | Hot Line I - Cardiovascular risk and complications | Salim Yusuf - Aldo Pietro Maggioni | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease | Hot Line I - Cardiovascular risk and complications | Ulrich Laufs - Philip Barter | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - the dal-VESSEL trial | Hot Line I - Cardiovascular risk and complications | Thomas Felix Luescher - Keith Fox | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trial | Hot Line I - Cardiovascular risk and complications | Christopher B Granger - Michael D Ezekowitz | Atrial Fibrillation | 28 Aug 2011 |
| CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trial | Hot Line I - Cardiovascular risk and complications | Massimo Imazio - Andre Keren | Pericardial Disease | 28 Aug 2011 |
| KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART Study | Clinical Trial Update I - Drug treatment | Takahisa Sawada - Josep Redon | Hypertension | 28 Aug 2011 |
| ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid lowering Arm | Clinical Trial Update I - Drug treatment | Peter S Sever - Guy De Backer | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial | Clinical Trial Update I - Drug treatment | Lars Wallentin - Jean-Philippe Collet | Atrial Fibrillation | 28 Aug 2011 |
| ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment | Clinical Trial Update I - Drug treatment | Keith A Fox - Stefan H Hohnloser | Atrial Fibrillation | 28 Aug 2011 |
| RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial | Clinical Trial Update I - Drug treatment | Antonio Miguel Dans - Freek Verheugt | Atrial Fibrillation | 28 Aug 2011 |
| ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trial | Clinical Trial Update I - Drug treatment | Michael Bohm - Luigi Tavazzi | Clinical pharmacology | 28 Aug 2011 |
| EUROACTION preventive cardiology programme plus intensive smoking cessation with Varenicline | Clinical Registry Highlight I - Risk and treatment reality | David Allan Wood | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| EUROASPIRE III: modelling the clinical and cost-effectiveness of optimizing cardiovascular prevention in patients with established coronary heart disease in Europe | Clinical Registry Highlight I - Risk and treatment reality | Lieven Annemans | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| Quality of care at discharge is affected by hospital case volume in acute myocardial infarction patients. A French nationwide assessment | Clinical Registry Highlight I - Risk and treatment reality | Francois Schiele | Cardiovascular Disease Prevention - Risk Assessment and Management | 28 Aug 2011 |
| Atrial fibrillation ablation European survey: short-term results. | Clinical Registry Highlight I - Risk and treatment reality | Josep Brugada Terradellas | Atrial Fibrillation | 28 Aug 2011 |
| GARFIELD: Multicentre international registry of patients newly diagnosed with atrial fibrillation at risk of stroke: the Garfield Registry | Clinical Registry Highlight I - Risk and treatment reality | Ajay Kakkar | Peripheral Arterial Diseases | 28 Aug 2011 |
| Global variation in the etiology and management of atrial fibrillation: results from a global atrial fibrillation registry | Clinical Registry Highlight I - Risk and treatment reality | Jeff Healey | Atrial Fibrillation | 28 Aug 2011 |
